A Phase 3 interventional study of Ixekizumab and Placebo in Plaque Psoriasis, sponsored by Eli Lilly and Company. Completed at 17 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-25.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Skin Diseases by Eli Lilly and Company — 1 open to participants now, 1 under way, 1 of them phase 3. Skin Diseases · Eli Lilly and Company.
Among the 11 studies in Skin Diseases by Eli Lilly and Company, this one is the 4th largest by enrollment, is the only one that started in 2018, is one of 9 in phase 3, and was the 3rd registered.
497 studies on the registry are indexed under Skin Diseases; 78 are open to participants now.
Browse Skin Diseases studies →1 of the 11 studies in Skin Diseases by Eli Lilly and Company is open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Australia and 9 more countries
Ages 6–17
By country, each count listing its studies:
Of the 55 Skin Diseases studies recruiting now, 27 (49%) set no upper age limit and 18 (33%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 438 is above the median of 70 across 375 interventional studies indexed under Skin Diseases.
Median enrollment 286 across the 11 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Skin Diseases by Eli Lilly and Company, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the efficacy and safety of the study drug ixekizumab in Chinese participants with moderate-to-severe plaque psoriasis.
Study I1F-MC-RHBH is a phase 3, multicenter, randomized, double-blind, placebo controlled, parallel-group study examining the effect of 2 dose regimens of ixekizumab versus placebo in participants with moderate-to-severe plaque psoriasis (Ps) during an induction dosing period with dosing for 12 weeks and the primary endpoint measured at 12 weeks, followed by a randomized, 48-week maintenance dosing period. During the maintenance dosing period, the study will evaluate the maintenance of response/remission, as well as relapse or rebound following treatment withdrawal, and response to retreatment following relapse.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received starting dose of 160 milligrams (mg) Ixekizumab at week 0 followed by 80mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection during induction period.
Drug: Ixekizumab
Participants received starting dose of 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab once every two weeks (Q2W) by subcutaneous injection during induction period.
Drug: Ixekizumab · Drug: Placebo
Participants received placebo every two weeks (Q2W) by subcutaneous (SC)injection during induction period.
Drug: Placebo
Administered SC
Also known as: LY2439821
Administered SC
Percentage of Participants With a Static Physician Global Assessment (sPGA) Score of Clear (0) or Minimal (1) With at Least a 2 Point Improvement
The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline.
Time frame: Week 12
Percentage of Participants Achieving a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75)
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).
Time frame: Week 12
Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of Clear (0) (Remission)
The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA assessed as 0, indicates complete resolution of plaque Ps.
Time frame: Week 12
Percentage of Participants Achieving a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90)
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).
Time frame: Week 12
Percentage of Participants Achieving a 100% Improvement in Psoriasis Area and Severity Index (PASI 100)
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).
Time frame: Week 12
Percentage of Participants Achieving an Itch Numeric Rating Scale (NRS) ≥4 Point Reduction From Baseline for Participants Who Had Baseline Itch NRS ≥4
The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 (no itch) and 10 (worst itch imaginable). Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.
Time frame: Week 12
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score
The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment). A score of 0 or 1 indicates no impact of disease on a participants quality of life. Least Square Mean (LS Mean) was calculated using Mixed Model Repeated Measures (MMRM) model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 12
Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score in Participants With Baseline Fingernail Involvement
NAPSI is a numeric, reproducible, objective tool for evaluation of fingernail(fn) Ps. This scale is used to evaluate severity of fn bed Ps \& fn matrix Ps by area of involvement in the fn unit. fn is divided with imaginary horizontal \& longitudinal lines into quadrants. Each fn is given a score for fn bed Ps 0(none) to 4(Ps in 4 quadrants of the fn) \& fn matrix Ps 0(none) to 4(Ps in 4 quadrants in matrix), depending on presence (score of 1) or absence (score of 0) of any of the features of fn bed or matrix Ps in each quadrant.NAPSI score of a fn is sum of scores in fn bed \& fn matrix from each quadrant (maximum of 8). Each fn is evaluated, then the sum of all fn equals the total NAPSI score with a range from range 0 to 80. Higher scores indicate more severe ps. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 12
Change From Baseline in Percent of Body Surface Area (BSA) Involvement of Psoriasis
The percentage involvement of psoriasis on each participant's body surface area was assessed by the investigator on a scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand including palm, fingers and thumb. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 12
Change From Baseline in Psoriasis Scalp Severity Index (PSSI) Score in Participants With Baseline Scalp Involvement
The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90%-100%) with a total score ranging from 0 (less severity) to 72 (more severity). LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 12
Change From Baseline in Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score
The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. Items from 8 domains contribute to the PCS. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 12
Change From Baseline in Medical Outcomes Study SF-36 Mental Component Summary (MCS) Score
The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. Items from 8 domains contribute to the PCS. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 12
Change From Baseline on Patient Global Assessment of Disease Severity
The Patient Global Assessment of Disease Severity is a single-item participant-reported outcome measure on which participants are asked to rate the severity of their psoriasis "today" from 0 (Clear) = no psoriasis, to 5 (Severe) = the worst their psoriasis has ever been. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 12
Change From Baseline in Palmoplantar PASI (PPASI) in Participants With Baseline Palmoplantar Involvement
The Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 (no Ps) to 72. (the most severe disease) The PPASI was only assessed if participants have palmoplantar psoriasis at baseline. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 12
Change From Baseline on the Joint Pain Visual Analog Scale (VAS)
The Joint Pain VAS is a participant-administered scale designed to measure current joint pain from PsA using a 100-mm horizontal VAS. Overall severity of a participant's joint pain from PsA is indicated by placing a single mark on the horizontal scale (0 = none; 100 = as severe as you can imagine). LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 12
Percentage of Participants With Anti-Ixekizumab Antibodies
Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.
Time frame: Baseline through Week 12
Responders were defined as achieving an sPGA score of 0 or 1. Non-responders were defined as having an sPGA score of \>1. Responders were monitored for relapse, relapse (loss of response) occurring after Week 12 (Visit 7) was defined as an sPGA score of ≥3. In Re-treatment (Maintenance) Period, participants who relapsed received continued treatment of ixekizumab 80 mg Q4W, regardless of their treatment assignment.
| Milestone | PBO-Induction Dosing Period | IXE80Q4W-Induction Dosing Period | IXE80Q2W-Induction Dosing Period | IXE80Q4W(Res)/PBO-Maintenance Dosing Period | IXE80Q4W(Res)/IXE80Q4W-Maintenance Dosing Period | IXE80Q2W(Res)/PBO-Maintenance Dosing Period | IXE80Q2W(Res)/IXE80Q4W-Maintenance Dosing Period | PBO(Res)/PBO-Maintenance Dosing Period | PBO(NonResp)/IXE80Q4W-Maintenance Dosing Period | IXE80Q4W(NonResp)/IXE80Q4W-Maintenance Dosing Period | IXE80Q2W(NonResp)/IXE80Q4W-Maintenance Dosing Period | PBO(Resp)/PBO-Re-treatment (Maintenance) Period | IXE80Q4W(Resp)/PBO-Re-treatment (Maintenance) Period | IXE80Q4W(Resp)/IXE80Q4W-Re-treatment (Maintenance) Period | IXE80Q2W(Resp)/PBO-Re-treatment (Maintenance) Period | IXE80Q2W(Resp)/IXE80Q4W-Re-treatment (Maintenance) Period | PBO-Follow-up Period | IXE80Q4W-Follow-up Period | IXE80Q2W-Follow-up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 88 | 174 | 176 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received at least one dose of study drug | 88 | 174 | 176 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 82 | 170 | 175 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 6 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 4 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | PBO-Induction Dosing Period | IXE80Q4W-Induction Dosing Period | IXE80Q2W-Induction Dosing Period | IXE80Q4W(Res)/PBO-Maintenance Dosing Period | IXE80Q4W(Res)/IXE80Q4W-Maintenance Dosing Period | IXE80Q2W(Res)/PBO-Maintenance Dosing Period | IXE80Q2W(Res)/IXE80Q4W-Maintenance Dosing Period | PBO(Res)/PBO-Maintenance Dosing Period | PBO(NonResp)/IXE80Q4W-Maintenance Dosing Period | IXE80Q4W(NonResp)/IXE80Q4W-Maintenance Dosing Period | IXE80Q2W(NonResp)/IXE80Q4W-Maintenance Dosing Period | PBO(Resp)/PBO-Re-treatment (Maintenance) Period | IXE80Q4W(Resp)/PBO-Re-treatment (Maintenance) Period | IXE80Q4W(Resp)/IXE80Q4W-Re-treatment (Maintenance) Period | IXE80Q2W(Resp)/PBO-Re-treatment (Maintenance) Period | IXE80Q2W(Resp)/IXE80Q4W-Re-treatment (Maintenance) Period | PBO-Follow-up Period | IXE80Q4W-Follow-up Period | IXE80Q2W-Follow-up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 47 | 92 | 50 | 100 | 3 | 79 | 31 | 23 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received at least one dose of study drug | 0 | 0 | 0 | 47 | 92 | 50 | 100 | 3 | 79 | 31 | 23 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 3 | 80 | 4 | 84 | 1 | 73 | 27 | 17 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 44 | 12 | 46 | 16 | 2 | 6 | 4 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 3 | 1 | 3 | 0 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 2 | 0 | 3 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Relapsed | 0 | 0 | 0 | 43 | 7 | 45 | 10 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Miscellaneous | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | PBO-Induction Dosing Period | IXE80Q4W-Induction Dosing Period | IXE80Q2W-Induction Dosing Period | IXE80Q4W(Res)/PBO-Maintenance Dosing Period | IXE80Q4W(Res)/IXE80Q4W-Maintenance Dosing Period | IXE80Q2W(Res)/PBO-Maintenance Dosing Period | IXE80Q2W(Res)/IXE80Q4W-Maintenance Dosing Period | PBO(Res)/PBO-Maintenance Dosing Period | PBO(NonResp)/IXE80Q4W-Maintenance Dosing Period | IXE80Q4W(NonResp)/IXE80Q4W-Maintenance Dosing Period | IXE80Q2W(NonResp)/IXE80Q4W-Maintenance Dosing Period | PBO(Resp)/PBO-Re-treatment (Maintenance) Period | IXE80Q4W(Resp)/PBO-Re-treatment (Maintenance) Period | IXE80Q4W(Resp)/IXE80Q4W-Re-treatment (Maintenance) Period | IXE80Q2W(Resp)/PBO-Re-treatment (Maintenance) Period | IXE80Q2W(Resp)/IXE80Q4W-Re-treatment (Maintenance) Period | PBO-Follow-up Period | IXE80Q4W-Follow-up Period | IXE80Q2W-Follow-up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 43 | 7 | 45 | 10 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 42 | 6 | 43 | 8 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Relapse | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | PBO-Induction Dosing Period | IXE80Q4W-Induction Dosing Period | IXE80Q2W-Induction Dosing Period | IXE80Q4W(Res)/PBO-Maintenance Dosing Period | IXE80Q4W(Res)/IXE80Q4W-Maintenance Dosing Period | IXE80Q2W(Res)/PBO-Maintenance Dosing Period | IXE80Q2W(Res)/IXE80Q4W-Maintenance Dosing Period | PBO(Res)/PBO-Maintenance Dosing Period | PBO(NonResp)/IXE80Q4W-Maintenance Dosing Period | IXE80Q4W(NonResp)/IXE80Q4W-Maintenance Dosing Period | IXE80Q2W(NonResp)/IXE80Q4W-Maintenance Dosing Period | PBO(Resp)/PBO-Re-treatment (Maintenance) Period | IXE80Q4W(Resp)/PBO-Re-treatment (Maintenance) Period | IXE80Q4W(Resp)/IXE80Q4W-Re-treatment (Maintenance) Period | IXE80Q2W(Resp)/PBO-Re-treatment (Maintenance) Period | IXE80Q2W(Resp)/IXE80Q4W-Re-treatment (Maintenance) Period | PBO-Follow-up Period | IXE80Q4W-Follow-up Period | IXE80Q2W-Follow-up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 375 | 2 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 344 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 31 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 19 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 6 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Miscellaneous | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 |
The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline.
| Percentage of participants | Placebo | Ixekizumab 80mg Q4W | Ixekizumab 80mg Q2W |
|---|---|---|---|
| Percentage of Participants With a Static Physician Global Assessment (sPGA) Score of Clear (0) or Minimal (1) With at Least a 2 Point Improvement | 3.4 (0.0 to 7.2) | 79.9 (73.9 to 85.8) | 86.4 (81.3 to 91.4) |
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).
| Percentage of participants | Placebo | Ixekizumab 80mg Q4W | Ixekizumab 80mg Q2W |
|---|---|---|---|
| Percentage of Participants Achieving a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) | 8.0 (2.3 to 13.6) | 87.4 (82.4 to 92.3) | 93.8 (90.2 to 97.3) |
The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA assessed as 0, indicates complete resolution of plaque Ps.
| Percentage of participants | Placebo | Ixekizumab 80mg Q4W | Ixekizumab 80mg Q2W |
|---|---|---|---|
| Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of Clear (0) (Remission) | 0.0 (0.0 to 0.0) | 35.6 (28.5 to 42.7) | 36.4 (29.3 to 43.5) |
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).
| Percentage of participants | Placebo | Ixekizumab 80mg Q4W | Ixekizumab 80mg Q2W |
|---|---|---|---|
| Percentage of Participants Achieving a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90) | 2.3 (0.0 to 5.4) | 75.9 (69.5 to 82.2) | 82.4 (76.8 to 88.0) |
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).
| Percentage of participants | Placebo | Ixekizumab 80mg Q4W | Ixekizumab 80mg Q2W |
|---|---|---|---|
| Percentage of Participants Achieving a 100% Improvement in Psoriasis Area and Severity Index (PASI 100) | 0.0 (0.0 to 0.0) | 29.3 (22.5 to 36.1) | 33.0 (26.0 to 39.9) |
The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 (no itch) and 10 (worst itch imaginable). Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.
| percentage of participants | Placebo | Ixekizumab 80mg Q4W | Ixekizumab 80mg Q2W |
|---|---|---|---|
| Percentage of Participants Achieving an Itch Numeric Rating Scale (NRS) ≥4 Point Reduction From Baseline for Participants Who Had Baseline Itch NRS ≥4 | 8.1 (1.3 to 14.8) | 76.6 (69.2 to 83.9) | 78.4 (71.2 to 85.6) |
The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment). A score of 0 or 1 indicates no impact of disease on a participants quality of life. Least Square Mean (LS Mean) was calculated using Mixed Model Repeated Measures (MMRM) model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| units on a scale | Placebo | Ixekizumab 80mg Q4W | Ixekizumab 80mg Q2W |
|---|---|---|---|
| Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score | 0.92 ± 0.495 | -8.60 ± 0.346 | -8.86 ± 0.343 |
NAPSI is a numeric, reproducible, objective tool for evaluation of fingernail(fn) Ps. This scale is used to evaluate severity of fn bed Ps \& fn matrix Ps by area of involvement in the fn unit. fn is divided with imaginary horizontal \& longitudinal lines into quadrants. Each fn is given a score for fn bed Ps 0(none) to 4(Ps in 4 quadrants of the fn) \& fn matrix Ps 0(none) to 4(Ps in 4 quadrants in matrix), depending on presence (score of 1) or absence (score of 0) of any of the features of fn bed or matrix Ps in each quadrant.NAPSI score of a fn is sum of scores in fn bed \& fn matrix from each quadrant (maximum of 8). Each fn is evaluated, then the sum of all fn equals the total NAPSI score with a range from range 0 to 80. Higher scores indicate more severe ps. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| units on a scale | Placebo | Ixekizumab 80mg Q4W | Ixekizumab 80mg Q2W |
|---|---|---|---|
| Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score in Participants With Baseline Fingernail Involvement | -1.26 ± 1.365 | -11.35 ± 0.967 | -10.07 ± 0.974 |
The percentage involvement of psoriasis on each participant's body surface area was assessed by the investigator on a scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand including palm, fingers and thumb. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| Percent of BSA | Placebo | Ixekizumab 80mg Q4W | Ixekizumab 80mg Q2W |
|---|---|---|---|
| Change From Baseline in Percent of Body Surface Area (BSA) Involvement of Psoriasis | -0.36 ± 1.660 | -35.32 ± 1.157 | -36.70 ± 1.146 |
The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90%-100%) with a total score ranging from 0 (less severity) to 72 (more severity). LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| units on a scale | Placebo | Ixekizumab 80mg Q4W | Ixekizumab 80mg Q2W |
|---|---|---|---|
| Change From Baseline in Psoriasis Scalp Severity Index (PSSI) Score in Participants With Baseline Scalp Involvement | -1.59 ± 0.787 | -18.33 ± 0.544 | -19.52 ± 0.539 |
The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. Items from 8 domains contribute to the PCS. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| units on a scale | Placebo | Ixekizumab 80mg Q4W | Ixekizumab 80mg Q2W |
|---|---|---|---|
| Change From Baseline in Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score | -1.812 ± 0.5492 | 4.417 ± 0.3815 | 4.724 ± 0.3766 |
The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. Items from 8 domains contribute to the PCS. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| units on a scale | Placebo | Ixekizumab 80mg Q4W | Ixekizumab 80mg Q2W |
|---|---|---|---|
| Change From Baseline in Medical Outcomes Study SF-36 Mental Component Summary (MCS) Score | -1.233 ± 0.7798 | 3.960 ± 0.5414 | 4.129 ± 0.5342 |
The Patient Global Assessment of Disease Severity is a single-item participant-reported outcome measure on which participants are asked to rate the severity of their psoriasis "today" from 0 (Clear) = no psoriasis, to 5 (Severe) = the worst their psoriasis has ever been. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| units on a scale | Placebo | Ixekizumab 80mg Q4W | Ixekizumab 80mg Q2W |
|---|---|---|---|
| Change From Baseline on Patient Global Assessment of Disease Severity | -0.5 ± 0.12 | -3.1 ± 0.08 | -3.1 ± 0.08 |
The Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 (no Ps) to 72. (the most severe disease) The PPASI was only assessed if participants have palmoplantar psoriasis at baseline. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| units on a scale | Placebo | Ixekizumab 80mg Q4W | Ixekizumab 80mg Q2W |
|---|---|---|---|
| Change From Baseline in Palmoplantar PASI (PPASI) in Participants With Baseline Palmoplantar Involvement | -2.99 ± 0.861 | -6.34 ± 0.688 | -7.78 ± 0.626 |
The Joint Pain VAS is a participant-administered scale designed to measure current joint pain from PsA using a 100-mm horizontal VAS. Overall severity of a participant's joint pain from PsA is indicated by placing a single mark on the horizontal scale (0 = none; 100 = as severe as you can imagine). LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| millimeter (mm) | Placebo | Ixekizumab 80mg Q4W | Ixekizumab 80mg Q2W |
|---|---|---|---|
| Change From Baseline on the Joint Pain Visual Analog Scale (VAS) | -12.2 ± 9.64 | -39.6 ± 5.48 | -37.4 ± 4.75 |
Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.
| percentage of participants | Placebo | Ixekizumab 80mg Q4W | Ixekizumab 80mg Q2W |
|---|---|---|---|
| Percentage of Participants With Anti-Ixekizumab Antibodies | 0 | 19 | 12.5 |
Collected over Up to 72 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PBO-Induction Dosing Period | 0/88 (0%) | 3/88 (3.4%) | 25/88 (28.4%) |
| IXE80Q4W-Induction Dosing Period | 0/174 (0%) | 2/174 (1.1%) | 89/174 (51.1%) |
| IXE80Q2W-Induction Dosing Period | 0/176 (0%) | 1/176 (0.6%) | 97/176 (55.1%) |
| IXE80Q4W(Res)/PBO-Maintenance Dosing Period | 0/47 (0%) | 1/47 (2.1%) | 24/47 (51.1%) |
| IXE80Q4W(Res)/IXE80Q4W-Maintenance Dosing Period | 0/92 (0%) | 5/92 (5.4%) | 68/92 (73.9%) |
| IXE80Q2W(Res)/PBO-Maintenance Dosing Period | 0/50 (0%) | 1/50 (2%) | 22/50 (44%) |
| IXE80Q2W(Res)/IXE80Q4W-Maintenance Dosing Period | 0/100 (0%) | 2/100 (2%) | 66/100 (66%) |
| PBO(Res)/PBO-Maintenance Dosing Period | 0/3 (0%) | 1/3 (33.3%) | 1/3 (33.3%) |
| PBO(NonResp)/IXE80Q4W-Maintenance Dosing Period | 1/79 (1.3%) | 5/79 (6.3%) | 58/79 (73.4%) |
| IXE80Q4W(NonResp)/IXE80Q4W-Maintenance Dosing Period | 0/31 (0%) | 0/31 (0%) | 22/31 (71%) |
| IXE80Q2W(NonResp)/IXE80Q4W-Maintenance Dosing Period | 0/23 (0%) | 1/23 (4.3%) | 14/23 (60.9%) |
| PBO(Resp)/PBO-Re-treatment (Maintenance) Period | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| IXE80Q4W(Resp)/PBO-Re-treatment (Maintenance) Period | 0/43 (0%) | 1/43 (2.3%) | 24/43 (55.8%) |
| IXE80Q4W(Resp)/IXE80Q4W-Re-treatment (Maintenance) Period | 0/7 (0%) | 0/7 (0%) | 4/7 (57.1%) |
| IXE80Q2W(Resp)/PBO-Re-treatment (Maintenance) Period | 0/45 (0%) | 2/45 (4.4%) | 27/45 (60%) |
| IXE80Q2W(Resp)/IXE80Q4W-Re-treatment (Maintenance) Period | 0/10 (0%) | 0/10 (0%) | 5/10 (50%) |
| PBO-Follow-up Period | 0/11 (0%) | 0/11 (0%) | 0/11 (0%) |
| IXE80Q4W-Follow-up Period | 0/375 (0%) | 7/375 (1.9%) | 27/375 (7.2%) |
| IXE80Q2W-Follow-up Period | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Event | PBO-Induction Dosing Period | IXE80Q4W-Induction Dosing Period | IXE80Q2W-Induction Dosing Period | IXE80Q4W(Res)/PBO-Maintenance Dosing Period | IXE80Q4W(Res)/IXE80Q4W-Maintenance Dosing Period | IXE80Q2W(Res)/PBO-Maintenance Dosing Period | IXE80Q2W(Res)/IXE80Q4W-Maintenance Dosing Period | PBO(Res)/PBO-Maintenance Dosing Period | PBO(NonResp)/IXE80Q4W-Maintenance Dosing Period | IXE80Q4W(NonResp)/IXE80Q4W-Maintenance Dosing Period | IXE80Q2W(NonResp)/IXE80Q4W-Maintenance Dosing Period | PBO(Resp)/PBO-Re-treatment (Maintenance) Period | IXE80Q4W(Resp)/PBO-Re-treatment (Maintenance) Period | IXE80Q4W(Resp)/IXE80Q4W-Re-treatment (Maintenance) Period | IXE80Q2W(Resp)/PBO-Re-treatment (Maintenance) Period | IXE80Q2W(Resp)/IXE80Q4W-Re-treatment (Maintenance) Period | PBO-Follow-up Period | IXE80Q4W-Follow-up Period | IXE80Q2W-Follow-up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HydrosalpinxReproductive system and breast disorders | 0/24 | 0/45 | 0/34 | 0/10 | 0/27 | 0/14 | 0/15 | 1/1 | 0/21 | 0/5 | 0/3 | 0/1 | 0/10 | 0/3 | 0/12 | 0/1 | 0/3 | 0/84 | 0/1 |
| PneumoniaInfections and infestations | 0/88 | 0/174 | 0/176 | 0/47 | 1/92 | 0/50 | 0/100 | 0/3 | 0/79 | 0/31 | 1/23 | 0/2 | 0/43 | 0/7 | 0/45 | 0/10 | 0/11 | 0/375 | 0/2 |
| Ectopic pregnancyPregnancy, puerperium and perinatal conditions | 0/24 | 0/45 | 0/34 | 0/10 | 1/27 | 0/14 | 0/15 | 0/1 | 0/21 | 0/5 | 0/3 | 0/1 | 0/10 | 0/3 | 0/12 | 0/1 | 0/3 | 0/84 | 0/1 |
| Hepatic function abnormalHepatobiliary disorders | 0/88 | 0/174 | 0/176 | 0/47 | 0/92 | 0/50 | 0/100 | 0/3 | 0/79 | 0/31 | 0/23 | 0/2 | 1/43 | 0/7 | 0/45 | 0/10 | 0/11 | 0/375 | 0/2 |
| Erythrodermic psoriasisSkin and subcutaneous tissue disorders | 2/88 | 0/174 | 0/176 | 0/47 | 0/92 | 0/50 | 0/100 | 0/3 | 0/79 | 0/31 | 0/23 | 0/2 | 0/43 | 0/7 | 0/45 | 0/10 | 0/11 | 0/375 | 0/2 |
| Arteriosclerosis coronary arteryCardiac disorders | 0/88 | 0/174 | 0/176 | 0/47 | 0/92 | 0/50 | 0/100 | 0/3 | 0/79 | 0/31 | 0/23 | 0/2 | 0/43 | 0/7 | 1/45 | 0/10 | 0/11 | 0/375 | 0/2 |
| AppendicitisInfections and infestations | 0/88 | 0/174 | 0/176 | 0/47 | 0/92 | 0/50 | 0/100 | 0/3 | 0/79 | 0/31 | 0/23 | 0/2 | 0/43 | 0/7 | 1/45 | 0/10 | 0/11 | 1/375 | 0/2 |
| Type 2 diabetes mellitusMetabolism and nutrition disorders | 0/88 | 0/174 | 0/176 | 1/47 | 0/92 | 0/50 | 0/100 | 0/3 | 0/79 | 0/31 | 0/23 | 0/2 | 0/43 | 0/7 | 0/45 | 0/10 | 0/11 | 1/375 | 0/2 |
| HypertensionVascular disorders | 0/88 | 0/174 | 0/176 | 1/47 | 0/92 | 0/50 | 0/100 | 0/3 | 0/79 | 0/31 | 0/23 | 0/2 | 0/43 | 0/7 | 0/45 | 0/10 | 0/11 | 0/375 | 0/2 |
| InfectionInfections and infestations | 0/88 | 0/174 | 0/176 | 0/47 | 0/92 | 1/50 | 0/100 | 0/3 | 0/79 | 0/31 | 0/23 | 0/2 | 0/43 | 0/7 | 0/45 | 0/10 | 0/11 | 0/375 | 0/2 |
| Event | PBO-Induction Dosing Period | IXE80Q4W-Induction Dosing Period | IXE80Q2W-Induction Dosing Period | IXE80Q4W(Res)/PBO-Maintenance Dosing Period | IXE80Q4W(Res)/IXE80Q4W-Maintenance Dosing Period | IXE80Q2W(Res)/PBO-Maintenance Dosing Period | IXE80Q2W(Res)/IXE80Q4W-Maintenance Dosing Period | PBO(Res)/PBO-Maintenance Dosing Period | PBO(NonResp)/IXE80Q4W-Maintenance Dosing Period | IXE80Q4W(NonResp)/IXE80Q4W-Maintenance Dosing Period | IXE80Q2W(NonResp)/IXE80Q4W-Maintenance Dosing Period | PBO(Resp)/PBO-Re-treatment (Maintenance) Period | IXE80Q4W(Resp)/PBO-Re-treatment (Maintenance) Period | IXE80Q4W(Resp)/IXE80Q4W-Re-treatment (Maintenance) Period | IXE80Q2W(Resp)/PBO-Re-treatment (Maintenance) Period | IXE80Q2W(Resp)/IXE80Q4W-Re-treatment (Maintenance) Period | PBO-Follow-up Period | IXE80Q4W-Follow-up Period | IXE80Q2W-Follow-up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PharyngitisInfections and infestations | 2/88 | 5/174 | 4/176 | 0/47 | 5/92 | 1/50 | 6/100 | 0/3 | 9/79 | 0/31 | 3/23 | 1/2 | 1/43 | 0/7 | 0/45 | 0/10 | 0/11 | 0/375 | 0/2 |
| Upper respiratory tract infectionInfections and infestations | 9/88 | 25/174 | 28/176 | 7/47 | 25/92 | 6/50 | 31/100 | 0/3 | 22/79 | 8/31 | 3/23 | 1/2 | 7/43 | 2/7 | 9/45 | 0/10 | 0/11 | 4/375 | 0/2 |
| Vitreous opacitiesEye disorders | 0/88 | 0/174 | 0/176 | 0/47 | 0/92 | 0/50 | 0/100 | 1/3 | 0/79 | 0/31 | 0/23 | 0/2 | 0/43 | 0/7 | 0/45 | 0/10 | 0/11 | 0/375 | 0/2 |
| Blood glucose decreasedInvestigations | 0/88 | 0/174 | 0/176 | 0/47 | 0/92 | 0/50 | 0/100 | 1/3 | 0/79 | 0/31 | 0/23 | 0/2 | 0/43 | 0/7 | 0/45 | 0/10 | 0/11 | 0/375 | 0/2 |
| TonsillitisInfections and infestations | 0/88 | 2/174 | 2/176 | 0/47 | 0/92 | 1/50 | 2/100 | 0/3 | 0/79 | 0/31 | 0/23 | 0/2 | 0/43 | 2/7 | 1/45 | 1/10 | 0/11 | 1/375 | 0/2 |
| Injection site reactionGeneral disorders | 0/88 | 13/174 | 19/176 | 0/47 | 17/92 | 0/50 | 17/100 | 0/3 | 8/79 | 3/31 | 2/23 | 0/2 | 3/43 | 1/7 | 5/45 | 1/10 | 0/11 | 0/375 | 0/2 |
| Blood glucose increasedInvestigations | 2/88 | 4/174 | 3/176 | 2/47 | 3/92 | 0/50 | 2/100 | 0/3 | 5/79 | 2/31 | 4/23 | 0/2 | 1/43 | 0/7 | 4/45 | 0/10 | 0/11 | 4/375 | 0/2 |
| NeutropeniaBlood and lymphatic system disorders | 0/88 | 0/174 | 2/176 | 0/47 | 3/92 | 1/50 | 1/100 | 0/3 | 0/79 | 0/31 | 0/23 | 0/2 | 1/43 | 1/7 | 0/45 | 0/10 | 0/11 | 0/375 | 0/2 |
| Injection site swellingGeneral disorders | 0/88 | 0/174 | 3/176 | 0/47 | 1/92 | 0/50 | 3/100 | 0/3 | 2/79 | 0/31 | 0/23 | 0/2 | 1/43 | 1/7 | 2/45 | 1/10 | 0/11 | 0/375 | 0/2 |
| NasopharyngitisInfections and infestations | 0/88 | 4/174 | 8/176 | 2/47 | 6/92 | 2/50 | 4/100 | 0/3 | 3/79 | 1/31 | 3/23 | 0/2 | 2/43 | 1/7 | 2/45 | 0/10 | 0/11 | 1/375 | 0/2 |
All randomized participants.
| Age, Continuous(years) | Placebo | Ixekizumab 80mg Q4W | Ixekizumab 80mg Q2W | Total |
|---|---|---|---|---|
| Mean | 41.9 ± 12.38 | 41.2 ± 11.59 | 39.2 ± 10.53 | 40.5 ± 11.37 |
| Sex: Female, Male(Participants) | Placebo | Ixekizumab 80mg Q4W | Ixekizumab 80mg Q2W | Total |
|---|---|---|---|---|
| Female | 24 | 45 | 34 | 103 |
| Male | 64 | 129 | 142 | 335 |
| Race (NIH/OMB)(Participants) | Placebo | Ixekizumab 80mg Q4W | Ixekizumab 80mg Q2W | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 88 | 174 | 176 | 438 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo | Ixekizumab 80mg Q4W | Ixekizumab 80mg Q2W | Total |
|---|---|---|---|---|
| China | 88 | 174 | 176 | 438 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Apr 2018 to primary completion in Jun 2020, 25 months.
Results were first posted in Jun 2021, 1 year after primary completion.
Of 58 industry-sponsored phase 3 interventional studies under Skin Diseases, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's 25 months is above that.
Counting every sponsor, half of 60 studies reached it within 19 months; a quarter within 13 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ixekizumab